HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 25, No. 10, October 2021 – An Inquiry into Life in the Universe       » A New Cell Factory for High-Purity DHA Production       » A New Nanoplatform With Dual-Mode Therapeutic Pathways       » Improving Breast Cancer Detection With New Liquid Biopsy Diagnosis Model       » Alginic Acid: The Secret to Building Better Bones       » Next Generation Genome Engineering With Mini CRISPR — Made Smaller to Deliver Better      
NEWS CRUNCH
Proteona Honoured with "one to watch" Prize in the Inaugural Spinoff Prize by Nature Research and Merck Group
Proteona Honoured with

SINGAPORE | 7th July 2020

Singapore-based biomedical company, Proteona, is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).

It has recently been selected by the Spinoff Prize as one of the top 44 science-based spin-off companies from around the world. The Spinoff Prize is established by Nature Research in partnership with the Merck Group. The award highlights spin-offs who take top-quality scientific research to the market and make a positive impact.

Proteona is recognized for addressing the clinical need in multiple myeloma, a blood cancer that is difficult to treat. Differences in drug response between patients and tumour clones within the same patient poses a great challenge in choosing the right treatment. Proteona leverages on single cell proteogenomics and artificial intelligence-assisted algorithms to measure tumour cell diversity in patient biopsy, which can help clinicians choose the best treatment for individual patient.

"It is a great honour to be recognized by the Spinoff Prize award, issued by Nature research, who represents the top scientific standard, and by Merck, an industry leader well known for its accelerator programs and technology innovation." Said Dr Andreas Schmidt, CEO of Proteona.

"It adds credibility to the science and business we are doing at Proteona, and provides momentum for us to achieve the next milestones. This comes just at the right moment for our upcoming fundraising campaign, which will be launched in a few weeks' time."

Proteona is one of the three Asia-based companies who made it to the prestigious list.

The Spinoff Prize application was open to all spinoff companies worldwide from fields of pharmaceuticals, agriculture, chemicals and digital technology. The companies were selected by a judging panel consisting of experts from Nature Research, Merck, and M Ventures. All companies were evaluated in five criteria: the science, the opportunity, the plan, the team, and the impact.

Proteona is committed to improving the clinical outcome of multiple myeloma. Proteona has recently been selected by Amgen as part of the Start-ups Meets Pharma program to improve multiple myeloma treatment selection.

FORTHCOMING ISSUE  
Launch of world-first expert resource to foster best practice osteoporosis care in the Asia Pacific
NEWS CRUNCH  
news Asia Summit on Global Health (ASGH) 2021 — Shaping a Resilient and Sustainable Future
news TechInnovation 2021 Virtual Exhibition to Showcase Sustainable Energy, Food, and Healthcare Solutions
news A New Approach for Effective Gout Treatment
news TechInnovation Returns from 28 to 30 September 2021
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy